University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 21 of 23

COMPLETED Phase 1

Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia

NCT00601224

COMPLETED Phase 4

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

NCT00494494

COMPLETED NA

Evaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)

NCT00494052

COMPLETED NA

Improving Decision Making About Feeding Options for Dementia

NCT01113749

COMPLETED

Maternal Oral Therapy to Reduce Obstetric Risk Kids

NCT03423836

COMPLETED NA

Family Partners for Health

NCT01378806

TERMINATED Phase 2

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

NCT00614458

COMPLETED

Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients

NCT00467532

COMPLETED Phase 1

Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements

NCT00466596

COMPLETED Phase 2

Oral Immunotherapy for Peanut Allergy (PMIT)

NCT00597675

COMPLETED NA

Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure

NCT00378950

TERMINATED Phase 2

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

NCT00617058

COMPLETED NA

Intervention for Newly Diagnosed Youth With HIV

NCT00510237

COMPLETED Phase 1

Study of Dust Mite Inhalation in Humans

NCT00448851

COMPLETED

C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions

NCT00271908

COMPLETED Phase 2

Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth

NCT00617240

COMPLETED NA

Randomized Control Trial to Assess Postoperative Pain After Sling Placement

NCT00746863

COMPLETED Phase 1

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet

NCT00766818

COMPLETED NA

Mechanisms Underlying Drug-Diet Interactions

NCT01034124

COMPLETED NA

The Effect of Yogurt Containing BB12 on Children's Health and Child Care Absenteeism

NCT00653705

COMPLETED Phase 1

Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders

NCT00609531

COMPLETED NA

Overcoming Psychiatric Barriers to the Treatment of Hepatitis C

NCT00407732

COMPLETED Phase 3

Xylitol Adult Caries Trial (X-ACT)

NCT00393055

TERMINATED Phase 2

5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis

NCT00450242

COMPLETED NA

Brain Imaging of Psychotherapy for Depression

NCT00609453

COMPLETED

Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

NCT00877942

COMPLETED NA

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

NCT00680693

COMPLETED Phase 1

Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma

NCT00386178

COMPLETED NA

Arthritis Self-Management Education Program

NCT00467064

TERMINATED Phase 1

Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis

NCT01028781

COMPLETED

Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease

NCT00903955

COMPLETED NA

Craniosacral Therapy in Migraine: A Feasibility Study

NCT00665236

COMPLETED

Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents

NCT00450918

COMPLETED Phase 4

Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic

NCT00381043

COMPLETED NA

Pharmacist-Administered Injections for Contraception

NCT00775047

COMPLETED

Cigarette Smoke and Susceptibility to Influenza Infection

NCT00448617

COMPLETED NA

C2P - Phase III: MPowerment and Community Promise

NCT00381784

COMPLETED NA

Life Skills Intervention for Adolescents Perinatally Infected With HIV

NCT00272519

TERMINATED Phase 1

Study of Valproic Acid to Treat HIV Infected Adults

NCT00312546

COMPLETED NA

Effect Of Obesity On Ozone-Induced Airway Inflammation

NCT00839943

COMPLETED

Examining the Link Between Trace Elements and Cardiovascular Disease Risk Factors in Young Adults

NCT00318734

COMPLETED

Rare Genetic Disorders of the Breathing Airways

NCT00323167

COMPLETED NA

Immunotherapy for Peanut Allergy

NCT00429429

COMPLETED NA

Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis

NCT00307216

COMPLETED

Metabolic Abnormalities - HIV Infected and Uninfected Males

NCT00260936

COMPLETED

PTSD and Risk Behavior in HIV Positive Female Adolescents

NCT00271882

TERMINATED NA

Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab

NCT00287378

COMPLETED

Intervention Development for Newly Diagnosed Youth With HIV

NCT00255892

COMPLETED

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

NCT00273273

COMPLETED NA

Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers

NCT00287365

← Previous Page 21 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.